# Mayo Clinic

ran a Phase 1 trial of the senolytic combination dasatinib plus quercetin (D+Q) in diabetic kidney disease, directly measuring reduced senescent-cell burden in treated patients.

Source: https://en.bioecon.ru/companies/mayo-clinic/
Updated: 2026-07-03

- Country: United States

## Technologies

- [Geroscience & senolytics](https://en.bioecon.ru/technology/geroscience-senolytics/)